Long-term efficacy and safety of ustekinumab in patients with moderate to severe psoriasis through 5 years of follow-up: results from the PHOENIX 1 long-term extension

被引：0
|
作者：
Kimball, A. B. [1 ,2 ]
Papp, K. A. [3 ]
Wasfi, Y. [4 ]
Chan, D. [4 ]
Bissonnette, R. [5 ]
Sofen, H. [6 ]
Yeilding, N. [4 ]
Li, S. [4 ]
Szapary, P. O. [4 ]
Gordon, K. B. [7 ,8 ]
机构：
[1] Harvard Univ, Sch Med, Boston, MA USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Prob Med Res, Waterloo, ON, Canada
[4] Janssen Res & Dev LLC, Spring House, PA USA
[5] Innovaderm Res Inc, Montreal, PQ, Canada
[6] Dermatol Res Associates, Los Angeles, CA USA
[7] N Shore Univ Hlth Syst, Chicago, IL USA
[8] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2012年 / 167卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：63 / 64
页数：2
相关论文
共 50 条
  • [41] Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis
    Zheng, Jianfeng
    Chen, Wenjuan
    Yi, Xuemei
    Yu, Ning
    Ding, Yangfeng
    Gao, Yunlu
    FRONTIERS IN MEDICINE, 2023, 10
  • [42] Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1)
    Imafuku, Shinichi
    Nakagawa, Hidemi
    Igarashi, Atsuyuki
    Morita, Akimichi
    Okubo, Yukari
    Sano, Shigetoshi
    Tada, Yayoi
    Nemoto, Osamu
    Rozzo, Stephen J.
    Kawamura, Masaki
    Ohtsuki, Mamitaro
    JOURNAL OF DERMATOLOGY, 2021, 48 (06): : 844 - 852
  • [43] Efficacy and Safety of Ustekinumab for Crohn's Disease: Results From IM-UNITI Long-Term Extension Through 3 Years
    Sandborn, William J.
    Rutgeerts, Paul
    Jacobstein, Douglas
    Gasink, Christopher
    Patel, Reese
    Zou, Bin
    Johanns, Jewel
    Sands, Bruce E.
    Hanauer, Stephen
    Targan, Stephan
    Ghosh, Subrata
    de Villiers, Willem
    Colombel, Jean-Frederic
    Feagan, Brian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S345 - S346
  • [44] Long-term Efficacy and Safety of Siponimod in Patients with SPMS: EXPAND Extension Analysis Up to 5 Years
    Kappos, Ludwig
    Giovannoni, Gavin
    Gold, Ralf
    Fox, Robert J.
    Vermersch, Patrick
    Benedict, Ralph H. B.
    Bar-Or, Amit
    Rouyrre, Nicolas
    Meier, Daniela Piani
    Ritter, Shannon
    Kilaru, Ajay
    Dahlke, Frank
    Karlsson, Goeril
    Cree, Bruce A. C.
    NEUROLOGY, 2020, 94 (15)
  • [45] Results of a long-term follow-up of transsexuals
    Rauchfleisch, U
    Barth, D
    Battegay, R
    NERVENARZT, 1998, 69 (09): : 799 - 805
  • [46] Long-term efficacy of ustekinumab with and without concomitant immunosuppressants for Crohn's disease: results from IM-UNITI long-term extension through 2 years
    Ghosh, S.
    Kramer, B. C.
    Gasink, C.
    Jacobstein, D.
    Adedokun, O. J.
    Gao, L. -L.
    Rutgeerts, P.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S459 - S460
  • [47] Long-Term Efficacy of Ustekinumab With and Without Concomitant Immunosuppressants for Crohn's Disease: Results From IM-UNITI Long-Term Extension Through 2 Years
    Sands, Bruce E.
    Kramer, Brian
    Gasink, Christopher
    Jacobstein, Douglas
    Adedokun, Omoniyi J.
    Gao, Long-Long
    Rutgeerts, Paul
    Ghosh, Subrata
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S329 - S329
  • [48] Pooled long-term safety analysis of risankizumab in patients with moderate to severe psoriasis
    Gordon, Kenneth B.
    Bachelez, Herve
    Blauvelt, Andrew
    Strober, Bruce
    Harbers, Stephanie
    Valdes, Joaquin
    Waterhouse, Brian
    Sinvhal, Ranjeeta
    Lebwohl, Mark
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB176 - AB176
  • [49] LONG-TERM (5 YEARS) FOLLOW-UP OF 200 PATIENTS WITH CORONARY SURGERY
    ENDO, M
    FUKUCHI, S
    HAYASHI, H
    WADA, J
    INOUE, Y
    SEKIGUCHI, M
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1980, 44 (08): : 670 - 670
  • [50] Long-term efficacy and safety of risankizumab (RZB) for the treatment of moderate to-severe plaque psoriasis: Interim analysis of results from the LIMMitless open-label extension trial beyond 4 years of follow-up
    Papp, Kim A.
    Lebwohl, Mark G.
    Puig, Lluis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB77 - AB77
12345